Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences, now Talon Therapeutics, in August 2007. Dr. Deitcher originally joined Talon (Hana) as Executive Vice President of Development and Chief Medical Officer in May 2007. Since joining the company, Dr. Deitcher has transformed the organization into a focused, expert, and well-capitalized oncology drug development company. He is responsible for the rapid advancement (acceleration and amplification) of the Marqibo and Menadione Programs in particular. Prior to joining Talon (Hana), Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 20 years of experience as a academic physician in hematology, medical oncology and clinical thrombosis vascular medicine.

Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special and molecular coagulation laboratory.

Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 190 peer-reviewed journal papers, abstracts and book chapters.

Thomas DeZao joined Talon Therapeutics in May 2012 as Vice President, Commercial Operations and Planning. Mr. DeZao's experience includes senior commercial and marketing positions related to hematologic cancer product candidates at ChemGenex Pharmaceuticals, Genitope Corporation, and Corixa/Coulter Pharmaceuticals. Prior to that, Mr. DeZao worked for Schering-Plough Corp. and Chiron Corp., where he spent 10 years in various product sales, marketing and commercialization positions.

Craig Carlson joined Talon Therapeutics as Vice President in March 2010 and was appointed Chief Financial Officer in April 2010. He is responsible for all finance, accounting and administrative functions of the Company. Most recently, Mr. Carlson served as Chief Financial Officer and Chief Operating Officer for a new business incubator focused primarily on applying life science technologies to high value niche opportunities worldwide, where he was responsible for managing several businesses, including four international subsidiaries. From 2006 to 2008, he was Chief Financial Officer of Neurobiological Technologies, Inc. and from 1993 to 2005 Mr. Carlson served as Chief Financial Officer and Chief Operating Officer of Cygnus, Inc.

Mr. Carlson received his M.B.A. from the Stanford Graduate School of Business, his M.S. Ed. from Hofstra University, and his B.A. in Political Science from Union College in Schenectady, N.Y.

Dr. Jeffrey Silverman joined Talon in May 2009 as Vice President of Clinical Pharmacology and Translational Research. Dr. Silverman also holds an Adjunct Professor position in the Department of Bioengineering and Therapeutic Sciences of the University of California, San Francisco. Dr. Silverman received his B.S. from Colorado State University and his Ph.D. from the University of Pittsburgh, School of Medicine. He completed his postdoctoral training at Dartmouth College Medical School and then became a National Research Council Staff Fellow and Senior Staff Fellow at the National Cancer Institute at the NIH. Dr. Silverman subsequently joined AvMax Inc. as Director of Molecular and Cellular Biology. In 2002 he joined Sunesis Pharmaceuticals as Senior Director of Pharmacology. In 2006 Dr. Silverman was recognized as a Fellow of the American Association of Pharmaceutical Scientists. Dr Silverman joined Talon (formerly Hana Biosciences) in 2009. Dr Silverman has made numerous contributions to the field of drug transporters and their role in pharmacokinetics and pharmacodynamics. His current interests focus on the role of drug transporters and drug metabolizing enzymes as determinants of optimal pharmacokinetic and pharmacodynamic properties.

Thomas J. Tarlow joined Talon Therapeutics in January 2009 and is responsible for the development and implementation of regulatory strategies and quality systems as well as managing all U.S. and foreign regulatory filings for the Company's pipeline of dose-intensifying and compliance-enhancing oncology product candidates. Prior to joining Talon, Mr. Tarlow served as Vice President, Regulatory Affairs and Document Archives for Tercica, Inc., where he directed, planned, and implemented global regulatory activities, and led the development and implementation of quality systems used to achieve compliance with regulatory requirements. Previously, he held various senior positions at Amgen, Inc., SUGEN, Inc. and ALZA Corporation. While at ALZA, Mr. Tarlow managed regulatory support for its liposomal formulation technology platforms and achieved U.S. FDA priority approval of DOXIL® for treatment of advanced ovarian cancer.

Mr. Tarlow received his MS in Comparative Pathology from University of California, Davis, and AB in Biology from University of California, Santa Cruz.

Steven R. Deitcher, M.D., was appointed President and Chief Executive Officer and a member of the Board of Directors for Talon Therapeutics in August 2007. Dr. Deitcher originally joined Talon as Executive Vice President of Development and Chief Medical Officer in May 2007. From 2004 until he joined Talon, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 15 years of experience as a practicing physician in hematology, medical oncology and vascular medicine. Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special coagulation laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and the International Society on Thrombosis and Hemostasis, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 185 journal papers, abstracts and book chapters and has made more than 35 scientific conference presentations. He was the founding editor-in-chief of the journal Current Hematology Reports.

Howard P. Furst, M.D., has served as a director of Talon since December 2009. Dr. Furst has over 20 years of experience in the healthcare industry and is currently a partner at Deerfield Management, a healthcare investment fund based in New York City, where he is primarily responsible for overseeing the firm's private investments. Prior to joining Deerfield Management in 2007, Dr. Furst was a portfolio manager for the healthcare group at Magnetar Capital, an investment fund, from 2006 to 2007. Prior to joining Magnetar Capital, Dr. Furst was a principal at Maverick Capital, an investment firm, where he was primarily responsible for managing the firm's investments in the pharmaceutical and biotechnology sectors. Dr. Furst received his M.D. from the New York University School of Medicine, an M.B.A. with a dual concentration in finance and healthcare administration from the Wharton School of Business at the University of Pennsylvania, and a B.A. from the University of Pennsylvania. Dr. Furst also serves as a director of NitroMed, Inc., a privately-held specialty pharmaceutical company.

Member of the Compensation Committee

Cecilia Gonzalo, is a Managing Director at Warburg Pincus LLC and a General Partner of Warburg Pincus & Co., where she focuses on healthcare investments in the biotechnology, pharmaceuticals and healthcare services sectors. Prior to joining Warburg Pincus in 2001, Ms. Gonzalo worked at Goldman Sachs in the Investment Banking Division focusing on corporate finance and mergers and acquisitions transactions in Latin America, as well as in the Principal Investment Area focusing on investments in the region. Ms. Gonzalo received a B.A., cum laude, in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School. Ms. Gonzalo also serves as a director of Allos Therapeutics and Rib-X Pharmaceuticals.

Committee Chair of the Compensation Committee

Paul V. Maier was appointed director of Talon in March 2008. Since November 2009, Mr. Maier has served as Chief Financial Officer of Sequenom, Inc., a publicly-held biotechnology company. From January 2007 until November 2009, he served as an independent financial consultant. From October 1992 to January 2007, Mr. Maier served as Senior Vice President, Chief Financial Officer of Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company based in San Diego, CA. Prior to joining Ligand, Mr. Maier served as Vice President, Finance at DFS West, a division of DFS Group, L.P., a private multinational retailer from October 1990 to October 1992. From February 1990 to October 1990, Mr. Maier served as Vice President and Treasurer of ICN Pharmaceuticals, Inc., a pharmaceutical and biotechnology research products company. Mr. Maier held various positions in finance and administration at SPI Pharmaceuticals, Inc., a publicly held subsidiary of ICN Pharmaceuticals Group, from 1984 to 1988, including Vice President, Finance from February 1984 to February 1987. Mr. Maier currently serves on the board of directors of Pure Bioscience, Inc. and International Stem Cell Corp., both publicly-held companies. Mr. Maier received an M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.

Committee Chair of the Audit Committee

Howard Pien, was appointed director of Talon in April 2012. Mr. Pien was most recently employed at Medarex, Inc. serving as President, Chief Executive Officer, and Chairman of the Board until Bristol-Myers Squibb acquired it in 2009. Prior to joining Medarex in 2007, Mr. Pien served as President, Chief Executive, and Chairman of the Board of Chiron Corporation from 2003 until 2006 (when Chiron was acquired by Novartis). He joined Chiron from GlaxoSmithKline (formerly SmithKline Beecham) where he served as President, Pharmaceuticals of SmithKline Beecham and later as President of GlaxoSmithKline's International Pharmaceutical business. Mr. Pien has also held positions in sales, market research, licensing and product management at Abbott Laboratories and Merck & Co. Mr. Pien earned a B.S. from the Massachusetts Institute of Technology and an M.B.A. from Carnegie-Mellon University.

Member of the Compensation Committee and Member of the Nominating and Corporate Governance Committee

Leon E. Rosenberg, M.D., has served on Talon's Board of Directors since February 2004 and has been the non-executive Chairman of the Board since March 2007. Dr. Rosenberg has been a Professor in the Princeton University Department of Molecular Biology and the Woodrow Wilson School of Public and International Public Affairs since 1997. Since July 1999, he has also been Professor Adjunct of Genetics at Yale University School of Medicine. From January 1997 to March 1998, Dr. Rosenberg served as Senior Vice President, Scientific Affairs of Bristol−Myers Squibb Company, and from September 1991 to January 1997, Dr. Rosenberg served as President of the Bristol−Myers Squibb Pharmaceutical Research Institute. From July 1984 to September 1991, Dr. Rosenberg was Dean of the Yale University School of Medicine. Dr. Rosenberg also serves on the Boards of Directors of Lovelace Respiratory Research Institute, Karo Bio AB, and Medicines for Malaria Venture. Dr. Rosenberg received B.A. an M.D. degrees, both summa cum laude, from the University of Wisconsin. He completed his internship and residency training in internal medicine at Columbia Presbyterian Medical Center in New York City.

Member of the Audit Committee
Committee Chair of the Nominating and Corporate Governance Committee

Robert J. Spiegel, M.D., was appointed a director in July 2010 after being designated by Warburg Pincus, pursuant to its rights under the June 2010 Investment Agreement. From 1983 unitl his retirement in November 2009, Dr. Spiegel was employed by Schering Plough, serving in a number of positions of increasing responsibility, including Chief Medical Officer from 1998 unitl 2009. Prior to joining Schering Plough, Dr. Spiegel was an Assistant Professor, Department of Medicine, NYU Medical Center. Dr. Spiegel obtained his M.D. from the University of Pennsylvania and a B.A., cum laude from Yale University. Dr. Spiegel also serves on the Boards of Geron Corporation and Capstone Therapeutics, Inc., both publicly-held biopharmaceutical companies.

Member of the Audit Committee and Member of the Nominating and Corporate Governance Committee

Elizabeth H. Weatherman , a director of Talon since January 2013, is a General Partner of Warburg Pincus & Co., a Managing Director of Warburg Pincus LLC and a member of the firm's Executive Management Group. Ms. Weatherman joined Warburg Pincus in 1988 and is currently responsible for the firm's U.S. healthcare investment activities. Ms. Weatherman currently serves on the board of directors of Tornier, Inc., Bausch + Lomb Incorporated and several other privately held companies. Previously, Ms. Weatherman served on the board of directors of ev3 Inc. and Kyphon, Inc. Ms. Weatherman earned a Master of Business Administration from the Stanford Graduate School of Business and a Bachelor of Arts from Mount Holyoke College.

Chief of the Division of Hematologic Neoplasia, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine, Dana-Farber Cancer Institute; Kraft Family Professor of Medicine, Harvard Medical School.

Kenneth C. Anderson, M.D. – Scientific Advisory Board Member. Dr. Anderson graduated from John Hopkins Medical School, trained in internal medicine at John Hopkins' Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as Chief of Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute. He serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; as well as on the Board of Directors and Chair of the Leadership Committee of the Multiple Myeloma Research Consortium. Ronald M. Bukowski , MD.

Professor of Medicine, Cleveland Clinic Foundation (CCF) Lerner College of Medicine of Case Western Reserve University; Emeritus Staff Consultant, CCF Taussig Cancer Center; Chairman Medical Advisory Committee, Kidney Cancer Association.

Professor of Medicine; Head of Hematology and Director of Hematology Research, Georgetown University Hospital; Chairman of the Lymphoma Committee of the Cancer and Leukemia Group B; Co-chair of the International Harmonization Project in Lymphoma and the AJCC Subcommittee on Lymphoma; President-Elect and Scientific Advisory Board Member of the Lymphoma Research.

Bruce D. Cheson, M.D., FACP, FAAS – Scientific Advisory Board Member. Dr. Cheson attended the University of Virginia and then Tufts University Medical School. He completed his internship and residency in Internal Medicine at the University of Virginia Hospitals and then a clinical and research fellowship in Hematology at New England Medical Center Hospital. From 1977-1984 he was Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of Utah. From 1986-2002, he was Head, Medicine Section, CTEP at the National Cancer Institute. Since 2002, Dr. Cheson has been Professor of Medicine, Head of Hematology and Director of Hematology Research at Georgetown University Hospital. Dr. Cheson has authored over 300 medical publications and abstracts and has contributed to over 50 texts. He is on the editorial board of numerous journals and is Associate Editor of the Journal of Clinical Oncology, Oncology, and Oncology News international. He is an Editor-in-Chief of Clinical Lymphoma and Myeloma and Clinical Advances in Hematology and Oncology. He has also been the editor of the American College of Physician's Medical Knowledge Assessment Program in Oncology and the ASCO SEP. He has served on several committees of the American Society of Clinical Oncology and was on its Board of Directors, and edited ASCO News and ASCO Daily News. From 2002-2006, he was on the Oncologic Drug Advisory Committee to the U.S. Food and Drug Administration. He currently chairs the Lymphoma Committee of the Cancer and Leukemia Group B, and is co-chair of the International Harmonization Project in Lymphoma and the AJCC Subcommittee on Lymphoma. He is on the Scientific Advisory Board of the Lymphoma Research Foundation and is its President-Elect. Dr. Cheson's clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies.

Founding Scientific Director, Centre for Drug Research and Development; Professor, Department of Biochemistry and Molecular Biology, University of British Columbia.

Professor of Medicine and Internist; Chair of the Department of Leukemia, University of Texas M.D. Anderson Cancer Center.

Hagop M. Kantarjian, M.D. – Scientific Advisory Board Member. Dr. Kantarjian is Professor and Chairman of University of Texas M. D. Anderson Cancer Center. He received his M.D. in 1979 from American University of Beirut, Beirut, Lebanon and completed his internship and residency at University of Beirut, Beirut, Lebanon in 1980. In addition, he received his Internal Medicine Degree in 1981 from American University of Beirut, Beirut, Lebanon and his Medical Oncology Subspecialty Degree in 1983 from Anderson Cancer Center, Houston, Texas. He has authored more than 700 peer-reviewed publications and 90 book chapters. In 2005, he was nominated as "America's Top Doctors", Castle Connolly Medical, 5th Edition, National Guide, Southwestern Region, Top Hematologist.

Director, Yale Cancer Center; Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven.

Thomas Lynch, Jr., M.D. – Scientific Advisory Board Member. Dr. Lynch is the Director of Yale Cancer Center and the Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven. Prior to his appointment to Yale, Dr. Lynch was an associate professor of medicine at Harvard Medical School and director of the Oncology Service Line at Dana-Farber Partners CancerCare. He received his M.D. in 1986 from Yale University and completed his internship and residency at MGH in 1989. Dr. Lynch served as a fellow in medical oncology at the Dana-Farber Cancer Institute from 1989-1991 and joined the Kenneth B. Schwartz Center in 1996, becoming Medical Director in 2000. In 2002 he assumed responsibility for the direction of the Oncology Service Line at Partners Healthcare. As director of the MGH Thoracic Oncology Center, Dr. Lynch worked with advanced fellows in thoracic oncology, leading to important contributions in developmental therapeutics, molecular epidemiology, and clinical economics. He is the author of numerous publications and maintains a vigorous clinical practice.

Dr. Maurie Markman is the new vice president of patient oncology services and national director for medical oncology at Cancer Treatment Centers of America. Dr. Markman has more than 20 years of experience in cancer treatment and gynecologic research at some of the country's most recognized facilities, including MD Anderson Cancer Center, the Cleveland Clinic and Memorial Sloan-Kettering.

Previously, Dr. Markman served as the vice president for clinical research and chairman of the department of gynecological medical oncology at MD Anderson, and chairman of the department of hematology/oncology at The Cleveland Clinic Foundation. He earned his medical degree from New York Medical University School of Medicine and holds a Master of Science degree in health policy and management from New York University Graduate School of Public Administration.